Prolia, a medication used to treat osteoporosis, has patents that are set to expire in the coming years.
When does Prolia's main patent expire?
The primary patent for Prolia (denosumab) is expected to expire in 2025 [1]. This date pertains to the formulation patent.
Are there other patents that could affect Prolia's market exclusivity?
Yes, in addition to the formulation patent, there are other patents related to Prolia's use and manufacturing that may expire at different times. DrugPatentWatch.com tracks these various patents and their expiry dates [1]. For instance, some method of use patents have expiry dates in the early 2030s [1].
What does patent expiry mean for Prolia?
Once key patents expire, it opens the door for other companies to develop and seek approval for generic versions of Prolia. This could potentially lead to increased competition and lower prices for patients [2].
How are these patent expiry dates determined?
Patent expiry dates are determined by the specific filing and grant dates of the patents, along with any patent term extensions that may have been granted. These extensions are often given to compensate for regulatory review periods. Information on these specific dates can be found on patent databases and specialized trackers like DrugPatentWatch.com [1].
What are the implications of Prolia patent expiry for biosimilar manufacturers?
For denosumab, as a biologic drug, the pathway for generic versions is known as biosimilars. The expiry of patents is a critical step for biosimilar manufacturers to prepare their applications and potentially launch their products. The specific market entry of biosimilars will depend on regulatory approvals and any remaining market exclusivity periods beyond patent expiry [2].